Rakovina Therapeutics to Present ATR Inhibitor Data in PTEN-Deficient Prostate Cancer at the 38th EORTC-NCI-AACR Symposium
6 Articles
6 Articles
Rakovina Therapeutics to Present ATR Inhibitor Data in PTEN-Deficient Prostate Cancer at the 38th EORTC-NCI-AACR Symposium
VANCOUVER, British Columbia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced that preclinical data from its kt-5000AI ATR inhibitor program…
Rakovina Therapeutics to Present ATR Inhibitor Data in PTEN-Deficient Prostate Cancer at the 38th EORTC-NCI-AACR Symposium - PressReach
VANCOUVER, British Columbia, Nov. 16, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced that preclinical data from its kt-5000AI ATR inhibitor program will be presented in a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and … Continue reading "Rakovina Therapeutics to …
Coverage Details
Bias Distribution
- 80% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium










